肺癌与表皮生长因子及其受体关系的研究

袁卫红; 罗志航; 彭荣宗; 杨雷; 张怡

肺癌与表皮生长因子及其受体关系的研究

袁卫红 , 罗志航 , 彭荣宗 , 杨雷 , 张怡

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 5: (261-263,267)

引用本文:

Citation:

肺癌与表皮生长因子及其受体关系的研究

650101 昆明, 昆明医学院第二附属医院核医学科

通讯作者: 袁卫红, yuantianhe@163.com ;

中图分类号: R730.43

The study on the correlation between EGF, EGFR and lung carcinoma

Department of Nuclear Medicine, The Second Affiliated Hospital, Kunming Medicial College, Kunming 650101, China

Corresponding author: YUAN Wei-hong, yuantianhe@163.com ;

CLC number: R730.43

摘要: 目的观察肺良性疾病、原发性肺癌患者表皮生长因子(EGF)及其受体(EGFR)在组织中不同表达及其与预后的关系。方法采用用免疫组化(IHC)法检测患者EGFR的表达;用放射免疫分析(RIA)法测定患者EGF的动态变化,并对肺癌患者进行随访。结果 EGFR在非小细胞肺癌(NSCLC)中表达88%(80/91),在癌旁组织中(距肿瘤边缘3cm以内)表达64%(58/91),较肺良性疾病(10%,10/95)高,差异有显著性意义(t=4.0,P<0.01),而距肿瘤边缘6cm以远的正常肺组织表达12%(11/91),与肺良性疾病差异无显著性意义(t=28,P>0105);小细胞肺癌不表达EGFR。肺癌患者术前血中EGF较肺良性疾病高,术后明显下降。EGFR表达阳性的NSCLC患者,术前EGF较阴性组高,术后逐渐下降,复发前、复发后升高,接近术前水平;EGFR表达阳性的NSCLC患者,术后6、12、18、24个月复发率分别为10%、55%、70%、81%,而EGFR表达阴性的复发率分别是0、13%、37%、50%。结论 EGFR与肺癌预后关系密切。
- 肺肿瘤 /
- 表皮生长因子 /
- 受体,表皮生长因子
Abstract: Objective To detect and observe the different expression and the prognosis relation between epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in benign lung disease and primary lung carcinoma. Methods To detect EGFR by immunohistochemical (IHC) ABC method. To test and follow-up survey the changes of EGF in lung cancer patients by radioimmunoassay(RIA). Results The level of EGFR in non-small cell lung carcinoma (NSCLC) was 88% (80/91), in tissues (3 centimetres nearby tumor) was 64%(58/91), in benign lung disease was 10% (4/39) (t=4.73, P<0.01). The level of EGFR in normal lung tissues (6 centimetres nearby tumor) was 12%(11/91), but these was no significante difference with benign lung disease (t=2.8, P>0.05). EGFR was not tested in NSCLC. Before operation, the level of EGF in lung cancer patients was higher than that of benign lung patients, but it decreased after operation. The EGF in NSCLC with positive EGFR pre-operation was higher than that of negative EGFR, but it decreased post operation, while pre and post-recurrence it increased approaching the pre-operation level. NSCLC patients with positive EGFR, the recurrence rate was 16%, 55%, 70% and 81% a second time 6, 12, 18 and 24 months after operation, while the recurrence rate with negative EGFR was 0, 13%, 37% and 50%, respectively. Conclusions EGFR may play important action in the lung cancer prognosis.
- Lung neoplasms /
- Epidermal growth factor /
- Receptor, epidermal growth factor
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Tiseo M,Loprevite M,Ardizzoni A,et al.Epidermal growth factor receptor inhibtors:a new prospective in the treatment of lung cancer.Curr Med Chem Anti Cancer Agents,2004,4(2):139-148.
[2]	Chan SK,Gullick WJ,Hill ME,et al.Mutations of the epidermal growth factor receptor in non-small-cell lung cancer search and destroy.Eur J Cancer,2006,42(1):17-23.
[3]	Lee D.Phase Ⅱ data with ZD6474,a small-molecule kinase inhibtor of epidermal growth factor receptor and vascular endothelial growth factor receptor,in previously treated advanced non-small-cell lung cancer.Clin Lung Cancer,2005,7(2):89-91.
[4]	Dazzi H,Hasleton PS,Thatcher N,et al.Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer.Use of archival tissue and correlation of EGF-R with histology,tumour size,node status and survival.Br J Cancer,1989,59(5):746-749.
[5]	Herbst RS,Bunn PA Jr.Targeting the epidermal growth factor receptor in non-small cell lung cancer.Clin Cancer Res,2003,9(16 pt 1):5813-5824.
[6]	Reddy GK,Lmaizumi M,Nishimura M,et al.Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibtors in non-small-cell lung cancer.Clin Lung Cancer,2005,7(3):163-165.

[1]	郑玉民 , 王自正 , 王峰 , 范我 . 以表皮生长因子受体为靶点的肿瘤分子靶向治疗. 国际放射医学核医学杂志, 2007, 31(1): 21-25.
[2]	汪永红 , 陈文新 , 何品玉 . 肿瘤表皮生长因子受体的分子显像研究. 国际放射医学核医学杂志, 2009, 33(4): 204-206. doi: 10.3760/cma.j.issn.1673-4114.2009.04.004
[3]	黄顺 , 韩彦江 , 郑希 , 赵肃清 , 吴湖炳 , 王全师 . 靶向表皮生长因子受体小分子类PET显像剂研究进展. 国际放射医学核医学杂志, 2017, 41(1): 50-58. doi: 10.3760/cma.j.issn.1673-4114.2017.01.010
[4]	周晓靓 , 王浩 , 施培基 , 刘鉴峰 , 孟爱民 . 表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展. 国际放射医学核医学杂志, 2013, 37(2): 100-103. doi: 10.3760/cma.j.issn.1673-4114.2013.02.010
[5]	夏俊勇 , 王火强 . 以血管内皮生长因子及其受体为靶向的肺癌放射性核素显像. 国际放射医学核医学杂志, 2008, 32(2): 82-85.
[6]	王相成 , 王雪梅 , 何玉 , 林白侠 . PET-CT表皮生长因子受体显像的研究进展. 国际放射医学核医学杂志, 2010, 34(5): 266-268. doi: 10.3760/cma.j.issn.1673-4114.2010.05.003
[7]	林潇 , 唐明灯 . 靶向表皮生长因子受体分子探针研究进展. 国际放射医学核医学杂志, 2015, 39(1): 85-90. doi: 10.3760/cma.j.issn.1673-4114.2015.01.018
[8]	郭睿 , 晋建华 . ^99mTc-depreotide生长抑素受体显像的临床应用研究. 国际放射医学核医学杂志, 2007, 31(3): 154-157.
[9]	侯仁花 , 吕中伟 . 生长抑素受体显像剂^99mTc-depreotide的研究进展. 国际放射医学核医学杂志, 2008, 32(1): 15-18.
[10]	黄道远 , 孝延龄 . ¹²³I-表皮生长因子淋巴闪烁显像术. 国际放射医学核医学杂志, 1992, 16(2): 93-93.

点击查看大图

计量

文章访问数: 1389
HTML全文浏览量: 76
PDF下载量: 2

肺癌与表皮生长因子及其受体关系的研究

通讯作者: 袁卫红, yuantianhe@163.com;

650101 昆明, 昆明医学院第二附属医院核医学科

收稿日期: 2006-03-21

关键词:

摘要: 目的观察肺良性疾病、原发性肺癌患者表皮生长因子(EGF)及其受体(EGFR)在组织中不同表达及其与预后的关系。方法采用用免疫组化(IHC)法检测患者EGFR的表达;用放射免疫分析(RIA)法测定患者EGF的动态变化,并对肺癌患者进行随访。结果 EGFR在非小细胞肺癌(NSCLC)中表达88%(80/91),在癌旁组织中(距肿瘤边缘3cm以内)表达64%(58/91),较肺良性疾病(10%,10/95)高,差异有显著性意义(t=4.0,P<0.01),而距肿瘤边缘6cm以远的正常肺组织表达12%(11/91),与肺良性疾病差异无显著性意义(t=28,P>0105);小细胞肺癌不表达EGFR。肺癌患者术前血中EGF较肺良性疾病高,术后明显下降。EGFR表达阳性的NSCLC患者,术前EGF较阴性组高,术后逐渐下降,复发前、复发后升高,接近术前水平;EGFR表达阳性的NSCLC患者,术后6、12、18、24个月复发率分别为10%、55%、70%、81%,而EGFR表达阴性的复发率分别是0、13%、37%、50%。结论 EGFR与肺癌预后关系密切。